Featured Research

from universities, journals, and other organizations

Infusing 'good' cholesterol protein may lower risk of subsequent heart attack

Date:
November 5, 2012
Source:
American Heart Association
Summary:
In early tests in humans, infusing the chief protein in "good" cholesterol rapidly boosted the body's ability to move cholesterol out of plaque-clogged arteries. If the approach succeeds in clinical trials, it could reduce the high risk of an early subsequent heart attack compared to drugs that raise good cholesterol levels more slowly.

An intravenous infusion of good cholesterol could reduce the risk of a subsequent heart attack, researchers reported at the American Heart Association's Scientific Sessions 2012.

In a small, early study, researchers noted that an intravenous infusion of the chief protein in high density lipoprotein (HDL or "good" cholesterol) seems to rapidly boost the body's ability to move cholesterol out of plaque-clogged arteries .

In the days and weeks after a heart attack or chest pain, patients are at high risk of another attack. Standard heart attack medications, such as aspirin and anti-platelet drugs, prevent clotting but don't help eliminate the underlying cause -- cholesterol that has built up in artery plaque.

Other HDL drugs, such as niacin and fibrates, which do attack the underlying cause, gradually raise HDL and may prevent heart attacks years after the start of therapy.

The study involves CSL112, an infusible and natural human formulation of Apolipoprotein A-1 (ApoA-1), the key protein in HDL particles that transports cholesterol from arteries and other tissues into the liver for disposal.

"In a current multi-center study, CSL112 will be administered as a short series of weekly IV infusions initiated shortly following a heart attack or heart-related chest pain," said Andreas Gille, M.D., Ph.D., lead author of the study and Head of Clinical and Translational Science Strategy at CSL Limited in Parkville, Australia. "Our aim is to address a significant gap in acute coronary syndrome management by reducing the high risk of early recurrent events."

Researchers studied markers of cholesterol movement in response to a single infusion of CSL112 at doses ranging from 5 to 135 mg/kg in 57 healthy volunteers.

Compared with a placebo infusion, they found:

  • Cholesterol extraction from cells rose immediately (up to 270 percent from baseline).
  • PreBeta1-HDL, a subfraction of HDL involved in cholesterol elimination, increased dramatically (up to 3,600 percent from baseline).

"Overall, CSL112 behaved as well or better than we expected and all the changes are consistent with the desired elevation in reverse cholesterol transport activity," Gille said. "We did not observe any unfavorable changes in the low density lipoprotein or 'bad' cholesterol-related biomarkers tested."

The safety and behavior of CSL112 in patients with stable heart disease is being evaluated in a multi-center trial.

Co-authors are Rachael Easton, M.D., Ph.D.; Samuel D. Wright, Ph.D.; and Charles L. Shear, Dr.P.H.


Story Source:

The above story is based on materials provided by American Heart Association. Note: Materials may be edited for content and length.


Cite This Page:

American Heart Association. "Infusing 'good' cholesterol protein may lower risk of subsequent heart attack." ScienceDaily. ScienceDaily, 5 November 2012. <www.sciencedaily.com/releases/2012/11/121105114618.htm>.
American Heart Association. (2012, November 5). Infusing 'good' cholesterol protein may lower risk of subsequent heart attack. ScienceDaily. Retrieved September 1, 2014 from www.sciencedaily.com/releases/2012/11/121105114618.htm
American Heart Association. "Infusing 'good' cholesterol protein may lower risk of subsequent heart attack." ScienceDaily. www.sciencedaily.com/releases/2012/11/121105114618.htm (accessed September 1, 2014).

Share This




More Health & Medicine News

Monday, September 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) — A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) — Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com
California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

Reuters - US Online Video (Aug. 30, 2014) — California lawmakers pass a bill requiring universities to adopt "affirmative consent" language in their definitions of consensual sex, part of a nationwide drive to curb sexual assault on campuses. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
New Drug Could Reduce Cardiovascular Deaths

New Drug Could Reduce Cardiovascular Deaths

Newsy (Aug. 30, 2014) — The new drug from Novartis could reduce cardiovascular deaths by 20 percent compared to other similar drugs. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins